The 14-week open-label, noncomparative multicenter trial was funded by Pfizer Global Pharmaceuticals, maker of both agents and of the new combination tablet.

• 由制造此二制剂及新的组合制剂的辉瑞药厂赞助，为期14周，开放标示、非比较性多机构试验。